NAD+: what a metabolism pilot measured, and what it did not

Evidence discussed: Small human metabolic pilot.

What the researchers studied

A pilot study tracked NAD+ and related compounds in blood and urine during a six-hour intravenous exposure. Investigators reported time-dependent changes, including delayed rises in some plasma measurements and increased urinary excretion of selected compounds. [1]

How to interpret the result

This described metabolism rather than testing energy, addiction-treatment or longevity claims. Small groups and short observation limit interpretation. Blood and urine changes do not establish improved wellbeing or delivery to every target tissue.

What readers can take from it

Tracking a molecule’s fate and proving health benefits are different tasks. This study does not validate the Energy Plus name or equivalence to a shop preparation.

This original editorial summary provides no diagnosis, dosing or treatment advice. The study did not test or certify a PeptiKing product.

Source

[1] Grant et al., human NAD+ metabolome pilot (2019). PMID: 31572171. Based on the PubMed-indexed abstract and record; full-text methods were not independently reviewed.